OpenBilldrug price receipt

NADAC week of 2026-10-14

ADALIMUMAB-AATY(CF) 40 MG/0.4 ML AUTOINJECTOR

For 1 unit (EA)

Pharmacies pay

$490.04 – $501.46 filed

1 × $490.03675 to $501.46018 per EA (the 2 NDCs differ)

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare

We don’t know yet

No Medicare reference price. Part D: The Part D file flags this drug’s average spending per dosage unit as an outlier, so OpenBill does not use it as a reference price. Part B: This NDC is not in the current quarter’s Medicare Part B NDC-HCPCS crosswalk, so it has no Part B payment limit.


The spread

We don’t know yet

There is no Medicare figure to compare with, so there is no spread.

Cost-plus estimate

$568.55 – $581.68 estimated

NADAC for the pack + 15% + $5.00 fee per fill

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

ADALIMUMAB-AATY(CF) 40 MG/0.4 ML AUTOINJECTOR is how the CMS NADAC file names this product. The FDA NDC Directory lists it as adalimumab-aaty, under the trade name “Adalimumab”.

FDA gives its dosage form as kit.

The labeler, the company named on the label, is CELLTRION USA, Inc.

FDA lists no Established Pharmacologic Class for it.

The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes).

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $490.04 – $501.46 for 1 unit (EA), depending on the NDC ($490.03675 to $501.46018 per EA), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 6, the CMS Covered Outpatient Drug Product File S/I/N drug category was not applied when grouping drugs for the calculation.

All 2 NDCs

Other strengths, forms and brands

1 other product in the NADAC file shares the FDA nonproprietary name adalimumab-aaty with ADALIMUMAB-AATY(CF) 40 MG/0.4 ML AUTOINJECTOR.

ProductPharmacies pay per unitMedicare per unit
ADALIMUMAB-AATY(CF) 40 MG/0.4 ML AUTOINJECTOR this page
generic · kit
$490.03675 to $501.46018 per EA filed
eff. 2026-09-23
We don’t know yet
YUFLYMA(CF) 40 MG/0.4 ML AUTOINJECTOR
brand · kit
$896.83875 to $912.214 per EA filed
eff. 2026-09-23
$3,487.76811 per EA filed
Part D 2024 average

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

What Medicare paid

We don’t know yet; the card above says why.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

Questions

Why does this page start at 1 unit (EA)?
NADAC prices this product per EA, and the FDA NDC Directory lists its 2 NDCs as dosage form “KIT” with no route. Only a tablet, capsule, lozenge or troche with route “ORAL”, or a tablet or film with route “SUBLINGUAL” or “BUCCAL”, starts at 30, and none of these is one. NADAC’s EA for it may be the whole kit or one item in it, and the files do not say which. So the card starts at 1 unit (EA) rather than guess how many make up a fill; change it to match your prescription.